Literature DB >> 25544876

Transitions of histopathologic criteria for diagnosis of nonalcoholic fatty liver disease during the last three decades.

Yoshihiro Ikura1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome, and is the most common type of chronic liver diseases in the majority of developed countries. NAFLD shows a wide spectrum of disorders including simple steatosis, nonalcoholic steatohepatitis (NASH), and cirrhosis. While simple steatosis is recognized to be benign and stable, NASH is considered to be an aggressive form of the disease progressing to cirrhosis. Currently, differentiation between NASH and simple steatosis can be done only by liver biopsy. Despite many proposals and revisions, the histological criteria for the differentiation have not been perfected yet. In this review article, the changes in the histopathologic criteria of NAFLD during the last three decades are summarized, and perspectives of the future changes are demonstrated. The discussion focuses on how pathologists have been dealing with "hepatocellular ballooning". Loose criteria, in which hepatocellular ballooning was not required for the diagnosis of NASH, were applied in many clinical studies published in around 2000's, whereas a strict criterion based on the presence/absence of hepatocellular ballooning was approved recently. Hence, simple and reliable methods of identifying ballooned hepatocytes are being sought. Clinical and pathological predictors of NAFLD-related hepatocarcinogenesis will also be sought in the future.

Entities:  

Keywords:  Cirrhosis; Hepatocellular ballooning; Hepatocellular carcinoma; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Year:  2014        PMID: 25544876      PMCID: PMC4269908          DOI: 10.4254/wjh.v6.i12.894

Source DB:  PubMed          Journal:  World J Hepatol


  59 in total

1.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

2.  Hepatocellular carcinomas can develop in simple fatty livers in the setting of oxidative stress.

Authors:  Yoshihiro Ikura; Eiji Mita; Shoji Nakamori
Journal:  Pathology       Date:  2011-02       Impact factor: 5.306

3.  Hepatocellular ballooning in NASH.

Authors:  Stephen Caldwell; Yoshihiro Ikura; Daniela Dias; Kosuke Isomoto; Akito Yabu; Christopher Moskaluk; Patcharin Pramoonjago; Winsor Simmons; Harriet Scruggs; Nicholas Rosenbaum; Timothy Wilkinson; Patsy Toms; Curtis K Argo; Abdullah M S Al-Osaimi; Jan A Redick
Journal:  J Hepatol       Date:  2010-06-25       Impact factor: 25.083

4.  Fatty liver persisting for up to 33 years. A follow-up of the inversen-roholm liver biopsy material.

Authors:  M Hilden; E Juhl; A C Thomsen; P Christoffersen
Journal:  Acta Med Scand       Date:  1973-12

Review 5.  Can NASH be diagnosed, graded, and staged noninvasively?

Authors:  Garfield A Grandison; Paul Angulo
Journal:  Clin Liver Dis       Date:  2012-06-26       Impact factor: 6.126

6.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

7.  Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations.

Authors:  Z M Younossi; T Gramlich; Y C Liu; C Matteoni; M Petrelli; J Goldblum; L Rybicki; A J McCullough
Journal:  Mod Pathol       Date:  1998-06       Impact factor: 7.842

8.  Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

Authors:  Valérie Paradis; Stéphane Zalinski; Emna Chelbi; Nathalie Guedj; Françoise Degos; Valérie Vilgrain; Pierre Bedossa; Jacques Belghiti
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

9.  Nonalcoholic steatohepatitis: an expanded clinical entity.

Authors:  B R Bacon; M J Farahvash; C G Janney; B A Neuschwander-Tetri
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

10.  The natural history of nonalcoholic fatty liver: a follow-up study.

Authors:  M R Teli; O F James; A D Burt; M K Bennett; C P Day
Journal:  Hepatology       Date:  1995-12       Impact factor: 17.425

View more
  5 in total

1.  Ameliorative effects of lutein on non-alcoholic fatty liver disease in rats.

Authors:  Xiang Qiu; Dan-Hong Gao; Xiao Xiang; Yu-Fang Xiong; Teng-Shi Zhu; Lie-Gang Liu; Xiu-Fa Sun; Li-Ping Hao
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

2.  The involvement of cell surface nucleolin in the initiation of CCR6 signaling in human hepatocellular carcinoma.

Authors:  Wei Qiu; Guangyi Wang; Xiaodong Sun; Junfeng Ye; Feng Wei; Xiaoju Shi; Guoyue Lv
Journal:  Med Oncol       Date:  2015-02-20       Impact factor: 3.064

Review 3.  Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.

Authors:  Jian-Jun Gao; Zhen-Yan Shi; Ju-Feng Xia; Yoshinori Inagaki; Wei Tang
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

4.  Hepatic Macrosteatosis Is Partially Converted to Microsteatosis by Melatonin Supplementation in ob/ob Mice Non-Alcoholic Fatty Liver Disease.

Authors:  Alessandra Stacchiotti; Gaia Favero; Antonio Lavazza; Igor Golic; Marija Aleksic; Aleksandra Korac; Luigi Fabrizio Rodella; Rita Rezzani
Journal:  PLoS One       Date:  2016-01-29       Impact factor: 3.240

5.  Characterization of two types of intranuclear hepatocellular inclusions in NAFLD.

Authors:  Suzan Schwertheim; Julia Kälsch; Holger Jastrow; Christoph Matthias Schaefer; Sarah Theurer; Saskia Ting; Ali Canbay; Heiner Wedemeyer; Kurt Werner Schmid; Hideo Andreas Baba
Journal:  Sci Rep       Date:  2020-10-06       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.